Abstract
Metabolic syndrome (MetS) is a cluster of central obesity, dyslipidaemia, insulin resistance and hypertension. MetS frequently co-exists with non-alcoholic fatty liver disease (NAFLD), which is characterized by fat accumulation in the liver in the absence of alcohol abuse, viral hepatitis and other causes of chronic liver diseases. Both MetS and NAFLD are associated with an increased risk for cardiovascular disease and type 2 diabetes mellitus. There are also other associations between MetS and NAFLD.
In the present narrative review, we discuss the links between MetS and NAFLD in terms of prevalence, risk factors and treatment (both lifestyle interventions and drug therapy). Such associations highlight the common pathophysiological pathways of these metabolic disorders, although data for an independent association are not robust. Nevertheless, NAFLD may be regarded as a hepatic manifestation of MetS.
Keywords: Non-alcoholic fatty liver disease, metabolic syndrome, cardiovascular risk, risk factors, anti-obesity drugs, antidiabetic drugs, hypolipidaemic drugs, antihypertensive drugs.
Current Vascular Pharmacology
Title:Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
Volume: 16 Issue: 3
Author(s): Niki Katsiki, Pablo Perez-Martinez, Panagiotis Anagnostis, Dimitri P. Mikhailidis*Asterios Karagiannis
Affiliation:
- Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London,United Kingdom
Keywords: Non-alcoholic fatty liver disease, metabolic syndrome, cardiovascular risk, risk factors, anti-obesity drugs, antidiabetic drugs, hypolipidaemic drugs, antihypertensive drugs.
Abstract: Metabolic syndrome (MetS) is a cluster of central obesity, dyslipidaemia, insulin resistance and hypertension. MetS frequently co-exists with non-alcoholic fatty liver disease (NAFLD), which is characterized by fat accumulation in the liver in the absence of alcohol abuse, viral hepatitis and other causes of chronic liver diseases. Both MetS and NAFLD are associated with an increased risk for cardiovascular disease and type 2 diabetes mellitus. There are also other associations between MetS and NAFLD.
In the present narrative review, we discuss the links between MetS and NAFLD in terms of prevalence, risk factors and treatment (both lifestyle interventions and drug therapy). Such associations highlight the common pathophysiological pathways of these metabolic disorders, although data for an independent association are not robust. Nevertheless, NAFLD may be regarded as a hepatic manifestation of MetS.
Export Options
About this article
Cite this article as:
Katsiki Niki , Perez-Martinez Pablo , Anagnostis Panagiotis , Mikhailidis P. Dimitri*, Karagiannis Asterios , Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?, Current Vascular Pharmacology 2018; 16 (3) . https://dx.doi.org/10.2174/1570161115666170621075619
DOI https://dx.doi.org/10.2174/1570161115666170621075619 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Latest Results for Anti-Angiogenic Drugs in Cancer Treatment
Current Pharmaceutical Design Non-invasive Estimation of Aortic Blood Pressures: A Close Look at Current Devices and Methods
Current Pharmaceutical Design BELFAST Centenarians: A Case of Optimal Cardiovascular Risk?
Current Pharmaceutical Design NADPH Oxidases in the Heart
Current Cardiology Reviews Overview of Hyperuricaemia and Gout
Current Pharmaceutical Design Transdermal Therapeutic System of Enalapril Maleate Using Piperidine as Penetration Enhancer
Current Drug Delivery Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based “Triple Therapy” Experience in Southern Italy
Reviews on Recent Clinical Trials Postoperative Delirium
Current Drug Targets Design of Second Generation Phosphodiesterase 5 Inhibitors
Current Topics in Medicinal Chemistry Interactions Between the Sympathetic Nervous System and Angiotensin System in Renovascular Hypertension
Current Hypertension Reviews Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations
CNS & Neurological Disorders - Drug Targets Atrial Fibrillation in Patients Undergoing Surgical Revascularization: An Update on Pharmacologic Prophylaxis
Cardiovascular & Hematological Agents in Medicinal Chemistry Vascular Effects of Phytoestrogens and Alternative Menopausal Hormone Therapy in Cardiovascular Disease
Mini-Reviews in Medicinal Chemistry Oral Antiplatelet and Anticoagulant Agents in the Prevention and Management of Ischemic Stroke
Current Pharmaceutical Design Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Current Drug Targets Cardiovascular and Renovascular Implications of COX-2 Inhibition
Current Pharmaceutical Design Hemolytic Uremic Syndrome in Children
Current Pediatric Reviews Various Presentations of Preeclampsia at Tertiary Care Hospital of Sindh: A Cross-Sectional Study
Current Hypertension Reviews Impact of Sex on Office White Coat effect Tail: A Review
Current Pharmaceutical Design